• Annemans L, Ayme S, Le CY, Facey K, Gunther P, Nicod E, et al. Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL). Orphanet J Rare Dis. 2017 Mar 10;12(1):50, 2017. PubMed: PM28283046
  • Banzi R, Gerardi C, Bertele’ V, Garattini S. Conditional approval of medicines by the EMA. BMJ. 2017 May 2;357:j2062, 2017 May 02. PubMed: PM28465401
  • Berger ML, Sox H, Willke RJ, Brixner DL, Eichler HG, Goettsch W, et al. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. Value Health. 2017 Sep;20(8):1003-8. PubMed: PM28964430
  • Berger ML, Sox H, Willke RJ, Brixner DL, Eichler HG, Goettsch W, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1033-9. PubMed: PM28913966
  • Bucek PM, Visnansky M, Mackovicova S, Tomek D. Drug Policy in Slovakia. Value Health Reg Issues. 2017 Sep;13:44-49, 2017 Sep:-49. PubMed: PM29073987
  • Brooks SS. Regulation and Device Development: Tips for Optimizing Your Experience With the Food and Drug Administration. Tech Vasc Interv Radiol. 2017 Jun;20(2):109-15. PubMed: PM28673647
  • Carbonneil C. New French Coverage with Evidence Development for Innovative Medical Devices: Improvements and Unresolved Issues. Value Health. 2017 Jan;20(1):178-9. PubMed: PM28212960
  • Carlson JJ, Chen S, Garrison LP, Jr. Performance-Based Risk-Sharing Arrangements: An Updated International Review. Pharmacoeconomics. 2017 Oct;35(10):1063-72. PubMed: PM28695544
  • Chen YC, Cheng HF, Yeh MK. Cell Therapy Regulation in Taiwan. Cell Transplant. 2017 Mar 13;26(3):483-92. PubMed: PM27697103
  • Ciani O, Wilcher B, van GA, Taylor RS. Linking the Regulatory and Reimbursement Processes for Medical Devices: The Need for Integrated Assessments. Health Econ. 2017 Feb;26 Suppl 1:13-29, 2017 Feb:-29. PubMed: PM28139087
  • Culig J, Antolic S, Szkultecka-Debek M. Drug Policy in Croatia. Value Health Reg Issues. 2017 Sep;13:27-30, 2017 Sep:-30. PubMed: PM29073984
  • Fuchs S, Olberg B, Panteli D, Perleth M, Busse R. HTA of medical devices: Challenges and ideas for the future from a European perspective. Health Policy. 2017 Mar;121(3):215-29. PubMed: PM27751533
  • Degtiar I. A review of international coverage and pricing strategies for personalized medicine and orphan drugs. Health Policy. 2017 Dec;121(12):1240-8. PubMed: PM29033060
  • de Groot S, van der LN, Franken MG, Blommestein HM, Leeneman B, van RE, et al. Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences. Value Health. 2017 Apr;20(4):627-36. PubMed: PM28408005
  • Ferrario A, Araja D, Bochenek T, Catic T, Danko D, Dimitrova M, et al. The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. Pharmacoeconomics. 2017 Dec;35(12):1271-85. PubMed: PM28836222
  • Goble JA, Ung B, van Boemmel-Wegmann S, Navarro RP, Parece A. Performance-Based Risk-Sharing Arrangements: U.S. Payer Experience. J Manag Care Spec Pharm.2017 Oct;23(10):1042-52. PubMed: PM28944728
  • Greenhalgh T, Fahy N, Shaw S. The Bright Elusive Butterfly of Value in Health Technology Development Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies”. Int.2017 May 29;j. health policy manag.. 7(1):81-5. PubMed: PM29325407
  • Grimm SE, Strong M, Brennan A, Wailoo AJ. The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment. Pharmacoeconomics. 2017 Dec;35(12):1287-96. PubMed: PM28849538
  • Gronning N. Data Management in a Regulatory Context. Front Med (Lausanne).2017;4:114, 2017. PubMed: PM28785556
  • Grossmann N, Del Paggio JC, Wolf S, Sullivan R, Booth CM, Rosian K, et al. Five years of EMA-approved systemic cancer therapies for solid tumours-a comparison of two thresholds for meaningful clinical benefit. Eur J Cancer. 2017 Sep;82:66-71, 2017 Sep:-71. PubMed: PM28648700
  • Inokuma Y. Pharmacovigilance of Regenerative Medicine Under the Amended Pharmaceutical Affairs Act in Japan. Drug Saf. 2017 Jun;40(6):475-82. PubMed: PM28299610
  • Irving E, van den BR, Welsing P, Walsh V, fonso-Cristancho R, Harvey C, et al. Series: Pragmatic trials and real world evidence: Paper 7. Safety, quality and monitoring. J Clin Epidemiol. 2017 Nov;91:6-12, 2017 Nov:-12. PubMed: PM28502812
  • Kalkman S, van Thiel GJMW, Zuidgeest MGP, Goetz I, Pfeiffer BM, Grobbee DE, et al. Series: Pragmatic trials and real world evidence: Paper 4. Informed consent. J Clin Epidemiol. 2017 Sep;89:181-187, 2017 Sep:-187. PubMed: PM28502809
  • Kawalec P, Tesar T, Vostalova L, Draganic P, Manova M, Savova A, et al. Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review. Front Pharmacol.2017;8:892, 2017. PubMed: PM29326583
  • Kempf E, Bogaerts J, Lacombe D, Liu L. ‘Mind the gap’ between the development of therapeutic innovations and the clinical practice in oncology: A proposal of the European Organisation for Research and Treatment of Cancer (EORTC) to optimise cancer clinical research. Eur J Cancer. 2017 Nov;86:143-149, 2017 Nov:-149. PubMed: PM28987771
  • Khozin S, Blumenthal GM, Pazdur R. Real-world Data for Clinical Evidence Generation in Oncology. J Natl Cancer Inst. 2017 Nov 1;109(11), 2017 Nov 01). PubMed: PM29059439
  • Kristensen FB, Lampe K, Wild C, Cerbo M, Goettsch W, Becla L. The HTA Core Model-10 Years of Developing an International Framework to Share Multidimensional Value Assessment. Value Health. 2017 Feb;20(2):244-50. PubMed: PM28237203
  • Lach K, Dziwisz M, Remuzat C, Toumi M. Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines. J Mark Access Health Policy. 2017;5(1):1355202, 2017. PubMed: PM28804603
  • Lehoux P, Miller FA, Daudelin G, Denis JL. Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies. Int. 2017 Jan 25;j. health policy manag.. 6(9):509-18. PubMed: PM28949463
  • Maignen F, Osipenko L, Pinilla-Dominguez P, Crowe E. Regulatory watch: Outcomes of early health technology assessment dialogues in medicinal product development. Nat Rev Drug Discov. 2017 Feb 2;16(2):79, 2017. PubMed: PM28148947
  • Maignen F, Osipenko L, Pinilla-Dominguez P, Crowe E. Integrating health technology assessment requirements in the clinical development of medicines: the experience from NICE scientific advice. Eur J Clin Pharmacol. 2017 Mar;73(3):297-305. PubMed: PM27942759
  • Makady A, De BA, Hillege H, Klungel O, Goettsch W, (on behalf of GetReal Work Package. What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews. Value Health. 2017 Jul;20(7):858-65. PubMed: PM28712614
  • Makady A, Ham RT, De BA, Hillege H, Klungel O, Goettsch W, et al. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies. Value Health. 2017 Apr;20(4):520-32. PubMed: PM28407993
  • Meinecke AK, Welsing P, Kafatos G, Burke D, Trelle S, Kubin M, et al. Series: Pragmatic trials and real world evidence: Paper 8. Data collection and management. J Clin Epidemiol. 2017 Nov;91:13-22, 2017 Nov:-22. PubMed: PM28716504
  • Miller KL, Woodcock J. Value Assessment in the Regulatory Context. Value Health. 2017 Feb;20(2):296-8. PubMed: PM28237213
  • Nazareth T, Ko JJ, Sasane R Frois C, Carpenter S, Demean S, et al. Outcomes-Based Contracting Experience: Research Findings from U.S. and European Stakeholders. J Manag Care Spec Pharm. 2017 Oct;23(10):1018-26. PubMed: PM28944734
  • Neyt M, Baeyens H, Pouppez C, Slegers P, Hulstaert F, Stordeur S, et al. Introduction of high-risk medical devices: national measures that can be taken under the current European legislation to put the patient interest central. Expert Rev Med Devices. 2017 Mar;14(3):181-8. PubMed: PM28128008
  • Novakovic T, Martin AP, Parker M, Ferrario A, Vukovic S, Landa K, et al. The value of innovation in decision-making in health care in Central Eastern Europe – The Sixth International Conference, 2 June 2017, Belgrade, Serbia. Expert rev. 2017 Dec;pharmacoecon. outcomes res. 17(6):519-21. PubMed: PM28946800
  • Olberg B, Fuchs S, Panteli D, Perleth M, Busse R. Scientific Evidence in Health Technology Assessment Reports: An In-Depth Analysis of European Assessments on High-Risk Medical Devices. Value Health. 2017 Dec;20(10):1420-6. PubMed: PM29241902
  • Oude RK, Kalkman S, Collier S, Ciaglia A, Worsley SD, Lightborne A, et al. Series: Pragmatic trials and real world evidence: Paper 3. Patient selection challenges and consequences. J Clin Epidemoil. 2017 Sep;89:173-180. PubMed: PM28502808
  • Pace J, Ghinea N, Kerridge I, Lipworth W. Caution needed in introduction of provisional approvals for medicines. Intern Med J. 2017 Nov;47(11):1321-4. PubMed: PM29105267
  • Parvizi N, Parvizi S. New Health Technologies: A UK Perspective Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies”. Int. 2017 May 9;j. health policy manag.. 6(12):721-2. PubMed: PM29172379
  • Schwartz JL. Real-World Evidence, Public Participation, and the FDA. Hastings Cent Rep. 2017 Nov;47(6):7-8. PubMed: PM29171057
  • Pauwels K, Huys I, Vogler S, Casteels M, Simoens S. Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future. Front Pharmacol.2017;8:171, 2017. PubMed: PM28420990
  • Shiroiwa T, Fukuda T, Ikeda S, Takura T. New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations. Health Policy. 2017 Aug;121(8):836-41. PubMed: PM28687183
  • Smith JA, Brindley DA. Conditional Approval Pathways: The “Special” Case of Global Regenerative Medicine Regulation. Rejuvenation Res. 2017 Feb;20(1):1-3. PubMed: PM28125919
  • Tarricone R, Torbica A, Drummond M, MedtecHTA Project Group. Key Recommendations from the MedtecHTA Project. Health Econ. 2017 Feb;26 Suppl 1:145-152, 2017 Feb:-152. PubMed: PM28139086
  • Toumi M, Jaroslawski S, Sawada T, Kornfeld A. The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements : Current Debate. Appl Health Econ Health Policy. 2017 Feb;15(1):5-11. PubMed: PM27581118
  • Vella BP, Ermisch M, Godman B, Martin AP, Van Den BJ, Bezmelnitsyna L, et al. Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation. Front Pharmacol. 2017;8:497, 2017. PubMed: PM28878667
  • Watson R. EU agrees tighter standards for medical devices. BMJ. 2016 Jun 1;353:i3058, 2016 Jun 01. PubMed: PM27251309
  • van de Wetering EJ, van EJ, Brouwer WB. The Challenge of Conditional Reimbursement: Stopping Reimbursement Can Be More Difficult Than Not Starting in the First Place! Value Health. 2017 Jan;20(1):118-25. PubMed: PM28212952
  • Wilk N, Wierzbicka N, Skrzekowska-Baran I, Mocko P, Tomassy J, Kloc K. Study types and reliability of Real World Evidence compared with experimental evidence used in Polish reimbursement decision-making processes. Public Health. 2017 Apr;145:51-58, 2017 Apr:-58. PubMed: PM28359391
  • Woolacott N, Corbett M, Jones-Diette J, Hodgson R. Methodological challenges for the evaluation of clinical effectiveness in the context of accelerated regulatory approval: an overview. J Clin Epidemiol. 2017 Oct;90:108-118, 2017 Oct:-118. PubMed: PM28709997
  • Worsley SD, Oude RK, Irving E, Lejeune S, Mol K, Collier S, et al. Series: Pragmatic trials and real world evidence: Paper 2. Setting, sites, and investigator selection. J Clin Epidemiol. 2017 Aug;88:14-20, 2017 Aug:-20. PubMed: PM28502811
  • Yao X, Ding J, Liu Y, Li P. The New Drug Conditional Approval Process in China: Challenges and Opportunities. Clin Ther. 2017 May;39(5):1040-51. PubMed: PM28431767
  • Yeung K, Li M, Carlson JJ. Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based Pricing. J Manag Care Spec Pharm. 2017 Oct;23(10):1010-5. PubMed: PM28944729
  • Yu JS, Chin L, Oh J, Farias J. Performance-Based Risk-Sharing Arrangements for Pharmaceutical Products in the United States: A Systematic Review. J Manag Care Spec Pharm.2017 Oct;23(10):1028-40. PubMed: PM28944733
  • Zuidgeest MGP, Goetz I, Groenwold RHH, Irving E, van Thiel GJMW, Grobbee DE, et al. Series: Pragmatic trials and real world evidence: Paper 1. Introduction. J Clin Epidemiol. 2017 Aug;88:7-13, 2017 Aug:-13. PubMed: PM28549929
  • Zuidgeest MGP, Welsing PMJ, van Thiel GJMW, Ciaglia A, fonso-Cristancho R, Eckert L, et al. Series: Pragmatic trials and real world evidence: Paper 5. Usual care and real life comparators. J Clin Epidemiol. 2017 Oct;90:92-98, 2017 Oct:-98. PubMed: PM28694123